KR20240089127A - 인터루킨-1 활동 억제제로서의 신규 치환된 설포닐우레아 화합물 - Google Patents
인터루킨-1 활동 억제제로서의 신규 치환된 설포닐우레아 화합물 Download PDFInfo
- Publication number
- KR20240089127A KR20240089127A KR1020247014041A KR20247014041A KR20240089127A KR 20240089127 A KR20240089127 A KR 20240089127A KR 1020247014041 A KR1020247014041 A KR 1020247014041A KR 20247014041 A KR20247014041 A KR 20247014041A KR 20240089127 A KR20240089127 A KR 20240089127A
- Authority
- KR
- South Korea
- Prior art keywords
- mixture
- mmol
- independently
- compound
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/121548 | 2021-09-29 | ||
| CN2021121548 | 2021-09-29 | ||
| PCT/US2022/077120 WO2023056264A1 (en) | 2021-09-29 | 2022-09-27 | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240089127A true KR20240089127A (ko) | 2024-06-20 |
Family
ID=84329267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247014041A Pending KR20240089127A (ko) | 2021-09-29 | 2022-09-27 | 인터루킨-1 활동 억제제로서의 신규 치환된 설포닐우레아 화합물 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240400561A1 (https=) |
| EP (1) | EP4408843A1 (https=) |
| JP (1) | JP2024538602A (https=) |
| KR (1) | KR20240089127A (https=) |
| CN (1) | CN118251393A (https=) |
| AU (1) | AU2022356377A1 (https=) |
| CA (1) | CA3233673A1 (https=) |
| IL (1) | IL311784A (https=) |
| MX (1) | MX2024003948A (https=) |
| WO (1) | WO2023056264A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11465992B2 (en) * | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| US11370776B2 (en) * | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| MX2020001776A (es) * | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| US11542255B2 (en) * | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| EP3668861A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| KR20200087759A (ko) * | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| GB201902327D0 (en) * | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
-
2022
- 2022-09-27 JP JP2024519269A patent/JP2024538602A/ja active Pending
- 2022-09-27 KR KR1020247014041A patent/KR20240089127A/ko active Pending
- 2022-09-27 WO PCT/US2022/077120 patent/WO2023056264A1/en not_active Ceased
- 2022-09-27 MX MX2024003948A patent/MX2024003948A/es unknown
- 2022-09-27 CN CN202280075492.3A patent/CN118251393A/zh active Pending
- 2022-09-27 AU AU2022356377A patent/AU2022356377A1/en active Pending
- 2022-09-27 IL IL311784A patent/IL311784A/en unknown
- 2022-09-27 CA CA3233673A patent/CA3233673A1/en active Pending
- 2022-09-27 EP EP22801649.9A patent/EP4408843A1/en active Pending
- 2022-09-27 US US18/696,901 patent/US20240400561A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL311784A (en) | 2024-05-01 |
| AU2022356377A1 (en) | 2024-04-11 |
| WO2023056264A1 (en) | 2023-04-06 |
| CN118251393A (zh) | 2024-06-25 |
| EP4408843A1 (en) | 2024-08-07 |
| JP2024538602A (ja) | 2024-10-23 |
| US20240400561A1 (en) | 2024-12-05 |
| MX2024003948A (es) | 2024-06-28 |
| CA3233673A1 (en) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019264475B2 (en) | Bcl-2 inhibitors | |
| KR101701663B1 (ko) | 3-치환된 피라졸 및 dlk 억제제로서의 용도 | |
| JP2024527570A (ja) | Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 | |
| JP2021107414A (ja) | コロニー刺激因子−１受容体（ｃｓｆ−１ｒ）阻害剤 | |
| CA3010900A1 (en) | Spiroheptane salicylamides and related compounds as inhibitors of rock | |
| EP4333899A1 (en) | Compounds for targeting degradation of bruton's tyrosine kinase | |
| EP4129996A1 (en) | Novel aminopyrimidine egfr inhibitor | |
| US20240109887A1 (en) | Novel substituted bicyclic aza-heterocycles as sos1 inhibitors | |
| CA2731432A1 (en) | Tri-cyclic pyrazolopyridine kinase inhibitors | |
| KR20150132170A (ko) | 야누스 키나제 억제제로서의 비-시클릭 시아노에틸피라졸로 피리돈 | |
| CN112513021B (zh) | RORγ拮抗剂及其在药物中的应用 | |
| KR20240044386A (ko) | Lpa 길항제로서의 신규 트리아졸-피리딘 치환된 피롤리디닐 및 테트라히드로-2h-피라닐 아세트산 화합물 | |
| CN119487006A (zh) | 作为pge2受体拮抗剂的酰胺化合物 | |
| WO2019169539A1 (en) | Novel oxa-and aza-tricyclic 4-pyridone-3-carboxylic acid for treatment and prophylaxis of hepatitis b virus infection | |
| KR20240089127A (ko) | 인터루킨-1 활동 억제제로서의 신규 치환된 설포닐우레아 화합물 | |
| CA2580831A1 (fr) | Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases | |
| US12338255B2 (en) | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | |
| HK40107097A (zh) | 作为白介素-1活性抑制剂的新型经取代的磺酰脲化合物 | |
| HK40116219A (zh) | 新型双环经取代的磺酰脲化合物作为白介素-1活性的抑制剂 | |
| EA052733B1 (ru) | Ингибиторы nlrp3 | |
| CN121843931A (zh) | Tyk2抑制剂及其组合物和方法 | |
| HK40102702A (zh) | 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |